UOC
FUSN

UBS O'Connor’s Fusion Pharmaceuticals Inc. Common Shares FUSN Stock Holding History

UBS O'Connor’s Portfolio FUSN Stock Details FUSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-213,107
Closed -$2.05M – 623
2023
Q4 		$2.05M Sell
213,107
-61,461
-22% -$299K 0.06% 168
2023
Q3 		$714K Hold
274,568
– – 0.01% 364
2023
Q2 		$1.28M Buy
274,568
+32,542
+13% +$141K 0.03% 358
2023
Q1 		$912K Buy
+242,026
New +$953K 0.02% 421
2022
Q4 		– Sell
-17,286
Closed -$52K – 474
2022
Q3 		$52K Buy
+17,286
New +$43.2K ﹤0.01% 860

Other funds holding FUSN

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS O'Connor's FUSN Position: Q1 2024 in Review

UBS O'Connor sold out of Fusion Pharmaceuticals Inc. Common Shares (FUSN) in Q1 2024, closing a stake of 213,107 shares — an estimated $2.05M sold.

UBS O'Connor first reported a position in FUSN in Q3 2022 and held it in 5 quarters. The position peaked at $2.05M in Q4 2023. 114 funds tracked by Wall St. Rank hold FUSN as of Q1 2024.

  • UBS O'Connor reported no remaining Fusion Pharmaceuticals Inc. Common Shares position as of Q1 2024 after selling out during the quarter.
  • UBS O'Connor sold 213,107 Fusion Pharmaceuticals Inc. Common Shares shares in Q1 2024, an estimated $2.05M.
  • UBS O'Connor first reported a position in Fusion Pharmaceuticals Inc. Common Shares in Q3 2022 and held it in 5 quarters.
  • UBS O'Connor's Fusion Pharmaceuticals Inc. Common Shares position peaked at $2.05M in Q4 2023.
  • 114 funds tracked by Wall St. Rank held Fusion Pharmaceuticals Inc. Common Shares as of Q1 2024.

Based on UBS O'Connor's 13F filing for Q1 2024, filed 15 May 2024.